T. Rowe Price Investment Management

T. Rowe Price Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

T. Rowe Price Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.59M	Buy	1,542,090 +50,681	+3%	+$386K	0.01%	542
2025 Q4	$11M	Buy	1,491,409 +790,417	+113%	+$4.83M	0.01%	547
2025 Q3	$4.58M	Sell	700,992 -27,774	-4%	-$149K	﹤0.01%	576
2025 Q2	$3.14M	Buy	728,766 +589,120	+422%	+$2.89M	﹤0.01%	589
2025 Q1	$523K	Buy	+139,646	New	+$1.19M	﹤0.01%	633

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $699M AUM 600.17% 1-Year Est. Return

Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return